CD39 Blockade Shows Potential in Early-Stage Lung Cancer

Published Date: 24 Apr 2026

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Read Full News

Latest News

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

News All Time

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Oncology Care Model’s Net Losses Well Exceed Savings

But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

New data show growing adoption of guidance to skip sentinel lymph node biopsy in older women with early breast cancer, though uptake remains slow and incomplete in the US.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Nodal Response After Chemo Helps Tailor Breast Radiotherapy

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising recurrence risk.

Recommended News For You

Early Tislelizumab May Boost PFS in Esophageal Cancer

Scientists discover the 'roadmap' that aggressive cancer uses to spread

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

Video: Liver transplant for patients with advanced colorectal cancer

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?

Sickle Cell Disease Drug Pulled From Global Markets

Recommended Articles For You

Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer 

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life 

Exploring the Latest Advances in PTLD Cancer Treatment 

Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

2.

Future of Lab-Developed Tests Still Taking Shape

3.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

4.

BMI is linked to heart damage from chemotherapy in breast cancer patients.

5.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

1.

An Overview Of Serum Osmolality: What Is It And How Can It Help You?

2.

Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access

3.

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment

4.

AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis

5.

Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

Efficient Management of First line ALK-rearranged NSCLC - Part III

5.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot